Jci_page_head_homepage_01 Jci_page_head_homepage_02
Kristina M. Fetalvero, Peisheng Zhang, Maureen Shyu, Benjamin T. Young, John Hwa, Roger C. Young, Kathleen A. Martin
Published in Volume 118, Issue 12
J Clin Invest. 2008; 118(12):3966–3979 doi:10.1172/JCI33800
Abstract | Full text | PDF
Options: View larger image (or click on image)
Jci0833800
Figure 13
PGI2 mimics iloprost-induced contractile apparatus and connexin 43 protein expression.

(A) Effect of PGI2 on PKA activity. Human uSMCs were treated for 20 min with PGI2 or iloprost at the concentrations indicated and subjected to in vitro PKA assay. The phosphorylated kemptide gel is shown. (B and C) Effect of PGI2 on contractile apparatus protein and connexin 43 expression. (B) Human uSMCs were treated with PGI2 every 1.5 h up to 6 h or with a single treatment of iloprost for 6 h at the concentrations indicated. Western blots were performed with antibodies against SM2-MHC, calponin, β-tubulin, and GAPDH. (C) uSMCs were subjected to a single treatment of 0.6 μmol/l PGI2 for the indicated times. Western blot analysis was performed with antibodies against SM2-MHC, h-caldesmon, connexin 43, and β-tubulin as a loading control.